Premium
Cytosine arabinoside in acute leukemia of childhood
Author(s) -
Traggis D. G.,
Dohlwitz A.,
Das L.,
Jaffe N.,
Moloney W. C.,
Hall T. C.
Publication year - 1971
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(1971)28:4<815::aid-cncr2820280402>3.0.co;2-o
Subject(s) - medicine , leukopenia , cytosine , vomiting , leukemia , gastroenterology , cytarabine , acute leukemia , acute lymphocytic leukemia , toxicity , lymphoblastic leukemia , dna , biology , genetics
Arabinosyl cytosine (Ara‐C), 25 mg/kg by rapid intravenous infusion twice a week, was administered to 84 children with acute lymphocytic leukemia (ALL) and 14 children with acute myelogenous leukemia (AML). Of 74 evaluable patients with ALL, there were 24 complete remissions (CR) for a rate of 32.4%. Of 12 evaluable patients with AML, there were 4 CR for a rate of 33.3%. Most remissions were less than 11 weeks in duration, whether or not maintained with Ara‐C, although 4 maintained remissions lasted 17–25 weeks. Toxicity consisted mainly of vomiting, leukopenia, and thrombocytopenia.